upcoming glp-1 drugs New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these at scale. Our The GLP-1 Drugs Revolution: How

Coronary Artery Plaque Volume and Obesity in Patients with Diabetes: The Factor-64 Study

A collusion responsible for NIDDM

The binding modes of the clinically most widely used DPP-4 inhibitors have been characterized and based on these findings, three different classes of DPP-4 inhibitors have been proposed: Class 1 comprises of saxagliptin and vildagliptin, interacting with the S1- and S2 subsites of the active center and covalently binding with Ser630 of the DPP-4 molecule

Do GLP-1 analogues have an impact on bone health

More high-quality studies will need to be done before making any conclusions about berberines effectiveness in supporting weight loss